Abstract library

595 results for "response evaluation".
#1805 Application of Parametric Contrast-Enhanced Ultrasound for Early Treatment Response Evaluation in Metastatic Hepatic Neuroendocrine Neoplasm
Introduction: Since shrinkage of lesions in patients with metastatic hepatic neuroendocrine neoplasm (MHNEN) receiving systemic therapy is rarely observed,limit of RECIST for evaluating treatment response gradually emerged.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: house physician Xiaona Lin
Authors: Lin X, Chen J, Xu M, Xie X, ...
#1644 Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: PPRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic GEPNETs
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Tessa Brabander
#667 Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors after Treatment with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) (unidimensional), Southwest Oncology Group (SWOG) solid tumor response criteria (bidimensional), and their modified variants (mRECIST/mSWOG) are used to assess treatment response in gastroenteropancreatic and thoracic neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Esther I Van Vliet
#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)
Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: PhD Paula Jimenez-Fonseca
#1721 Optimisation of the Size Variation Threshold for CT Evaluation of Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors Treated with Octreotide LAR
Introduction: In advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), somatostatin analogs treatment rarely achieve a reduction of -30% in the sum of longest diameters (SLD) of target lesions required by Response Evaluation Criteria in Solid Tumors (RECIST) for an ‘objective response’. The implication of Stable Disease (SD) as an additional indicator of therapeutic effect is often uncertain.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Yanji Luo
Authors: Luo Y, Chen J, ...
#642 Correlation Between Chromogranin A and RECIST in Neuroendocrine Tumors’ Treatment
Introduction: High Chromogranin A (CGA) levels have been associated with both tumor burden and the secretory activity of GEPNETs specially carcinoids.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: PhD MD Paula Jimenez Fonseca
#1118 Is There an Additional Value of Somatostatin Receptor Subtype 2A Immunohistochemistry Over Somatostatin Receptor Scintigraphy in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
Introduction: It is not known whether tumoral somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) has additional value over OctreoScan® uptake in predicting response to PRRT in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: MD Roxanne Van Adrichem
Keywords: sst2a
#1334 Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?
Introduction: There is no study to assess RECIST and Choi criteria in evaluating response of advanced GEP-NENs treated with sunitinb.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Yanji Luo
Authors: Luo Y, Chen J, Li Z P, Feng S T, ...
#898 Evaluation of Tumor Response to Targeted Therapies in Precision-Cut Slices of Human Pancreatic Neuroendocrine Tumors
Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Margot Bucau
#804 The Plasma Chromogranin A Level Predicts Survival and Tumor Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Introduction: The plasma chromogranin A (CgA) level is a reliable biomarker for identifying patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: M.D. Tsann-Long Hwang
Authors: Chou W C, Chen J S, Hsu J T, Chen T C, ...